Is Buying Xbiotech Inc (NASDAQ:XBIT), Having Lower Short Interest a Winning Strategy?

October 1, 2018 – By Jack Shaw

XBiotech Inc. (NASDAQ:XBIT) Logo

The stock of Xbiotech Inc (NASDAQ:XBIT) registered a decrease of 4.21% in short interest. XBIT’s total short interest was 2.53M shares in October as published by FINRA. Its down 4.21% from 2.64M shares, reported previously. With 36,500 shares average volume, it will take short sellers 69 days to cover their XBIT’s short positions. The short interest to Xbiotech Inc’s float is 12.85%.

The stock increased 1.26% or $0.04 during the last trading session, reaching $3.22. About 43,077 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 36.41% since October 1, 2017 and is downtrending. It has underperformed by 52.03% the S&P500.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $115.34 million. The company??s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: which released: “2 Surging Drug Stocks Seeing Heavy Options Trading” on September 26, 2018, also with their article: “XBiotech Announces Completion of US Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients …” published on September 24, 2018, published: “XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases” on September 26, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: and their article: “Pre-Open Movers 09/13: (PI) (XBIT) (GNC) Higher; (PVTL) (PGNX) (FRED) Lower (more…)” published on September 13, 2018 as well as‘s news article titled: “XBiotech’s bermekimab shows positive effect dermatitis pilot study; shares up 28% premarket” with publication date: September 13, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *